BQ Prime's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer BQ Prime's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Systematix Research Report
Sun Pharmaceutical Industries Ltd.'s Q2 FY23 earnings were in line with our estimates. India branded formulations and specialty pharma growth remained strong.
The company's commentary on its specialty business remains encouraging. They expect the key specialty assets – Ilumya, Winlevi and Cequa – to continue to deliver growth going forward too.
Overall, Sun Pharma's portfolio continues to favorably transition to branded assets. The key growth levers for the company in FY24 are-
high single digit to low double digit growth in India, emerging markets and specialty assets which contribute about 72% of revenue,
launch of complex generic assets in the U.S. (including gRevlimid),
turnaround in its Taro subsidiary,
leveraging balance sheet for opportunistic acquisitions and in licensing deals,
improved realisation in Winlevi led by improving insurance coverage.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
